NHS could save millions by switching cervical cancer vax allegience; NIH and NanoBio fight RSV;

Vaccine Market

According to a study from the Health Protection Agency, the NHS could save millions of pounds by switching its cervical cancer vaccine allegiance from GlaxoSmithKline's Cervarix to Sanofi Pasteur MSD's Gardasil. Report

The National Institutes of Health has licensed an antigen to NanoBio to help develop a vaccine against respiratory syncytial virus. Item

Despite threats of jail time, many Nigerian parents refuse to allow their children to be vaccinated against polio. In a single district, more than 200 parents have refused to take part in vaccination efforts. More

And Finally... New promise for liver transplant patients: Pandemic flu vaccines showed modest seroconversion rates in a study in Liver Transplantation. Article

Suggested Articles

GSK's Shingrix supply has recovered after COVID-19 prompted a slowdown in vaccinations.

To eradicate SARS-CoV-2, we'll need a vaccine that's 70% effective—and 70% of the population will need to receive it, an FDA official says.

The U.K. government, fearing losing the supply race, agreed to buy 60 million doses of GSK-Sanofi's COVID-19 vaccine even before phase 1.